Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor.

Nadeau J, Smith T, Lamontagne-Proulx J, Bourque M, Al Sweidi S, Jayasinghe D, Ritchie S, Di Paolo T, Soulet D.

Brain Res. 2019 Dec 15;1725:146460. doi: 10.1016/j.brainres.2019.146460. Epub 2019 Sep 13.

PMID:
31525350
2.

Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease.

Jarras H, Bourque M, Poirier AA, Morissette M, Coulombe K, Di Paolo T, Soulet D.

J Neuroendocrinol. 2019 Aug 20:e12782. doi: 10.1111/jne.12782. [Epub ahead of print]

PMID:
31430407
3.

Drug repurposing: Old drugs, new tricks to fast track drug development for the brain.

Gasparini F, Di Paolo T.

Neuropharmacology. 2019 Mar 15;147:1-3. doi: 10.1016/j.neuropharm.2019.01.009. Epub 2019 Jan 11. Review. No abstract available.

PMID:
30641079
4.

An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.

Charvin D, Di Paolo T, Bezard E, Gregoire L, Takano A, Duvey G, Pioli E, Halldin C, Medori R, Conquet F.

Mov Disord. 2018 Oct;33(10):1619-1631. doi: 10.1002/mds.27462. Epub 2018 Sep 14.

PMID:
30216534
5.

Evidence for Sprouting of Dopamine and Serotonin Axons in the Pallidum of Parkinsonian Monkeys.

Gagnon D, Eid L, Coudé D, Whissel C, Di Paolo T, Parent A, Parent M.

Front Neuroanat. 2018 May 15;12:38. doi: 10.3389/fnana.2018.00038. eCollection 2018.

6.

Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease.

Bourque M, Morissette M, Di Paolo T.

Neuropharmacology. 2019 Mar 15;147:37-54. doi: 10.1016/j.neuropharm.2018.04.005. Epub 2018 Apr 9. Review.

PMID:
29649433
7.

Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors.

Mosher LJ, Godar SC, Morissette M, McFarlin KM, Scheggi S, Gambarana C, Fowler SC, Di Paolo T, Bortolato M.

Psychoneuroendocrinology. 2018 May;91:95-104. doi: 10.1016/j.psyneuen.2018.02.007. Epub 2018 Feb 16.

8.

Membrane cholesterol removal and replenishment affect rat and monkey brain monoamine transporters.

Morissette M, Morin N, Rouillard C, Di Paolo T.

Neuropharmacology. 2018 May 1;133:289-306. doi: 10.1016/j.neuropharm.2018.01.039. Epub 2018 Jan 31.

PMID:
29407218
9.

Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice.

Litim N, Morissette M, Caruso D, Melcangi RC, Di Paolo T.

J Steroid Biochem Mol Biol. 2017 Nov;174:242-256. doi: 10.1016/j.jsbmb.2017.09.021. Epub 2017 Oct 2.

PMID:
28982631
10.

The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.

Bourque M, Grégoire L, Di Paolo T.

Behav Brain Res. 2018 Jan 30;337:183-185. doi: 10.1016/j.bbr.2017.09.023. Epub 2017 Sep 14.

PMID:
28917506
11.

Plasmalogen precursor mitigates striatal dopamine loss in MPTP mice.

Miville-Godbout E, Bourque M, Morissette M, Al-Sweidi S, Smith T, Jayasinghe D, Ritchie S, Di Paolo T.

Brain Res. 2017 Nov 1;1674:70-76. doi: 10.1016/j.brainres.2017.08.020. Epub 2017 Aug 19.

PMID:
28830769
12.

Non-human primate models of PD to test novel therapies.

Morissette M, Di Paolo T.

J Neural Transm (Vienna). 2018 Mar;125(3):291-324. doi: 10.1007/s00702-017-1722-y. Epub 2017 Apr 8. Review.

PMID:
28391443
13.

Effects of progesterone administered after MPTP on dopaminergic neurons of male mice.

Litim N, Morissette M, Di Paolo T.

Neuropharmacology. 2017 May 1;117:209-218. doi: 10.1016/j.neuropharm.2017.02.007. Epub 2017 Feb 10.

PMID:
28192111
14.

Gastrointestinal Dysfunctions in Parkinson's Disease: Symptoms and Treatments.

Poirier AA, Aubé B, Côté M, Morin N, Di Paolo T, Soulet D.

Parkinsons Dis. 2016;2016:6762528. doi: 10.1155/2016/6762528. Epub 2016 Dec 6. Review.

15.

Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson's disease.

Poirier AA, Côté M, Bourque M, Morissette M, Di Paolo T, Soulet D.

Neurobiol Aging. 2016 Dec;48:61-71. doi: 10.1016/j.neurobiolaging.2016.08.004. Epub 2016 Aug 16.

PMID:
27644075
16.

The number of striatal cholinergic interneurons expressing calretinin is increased in parkinsonian monkeys.

Petryszyn S, Di Paolo T, Parent A, Parent M.

Neurobiol Dis. 2016 Nov;95:46-53. doi: 10.1016/j.nbd.2016.07.002. Epub 2016 Jul 5.

PMID:
27388937
17.

Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.

Litim N, Morissette M, Di Paolo T.

Neuropharmacology. 2017 Mar 15;115:166-179. doi: 10.1016/j.neuropharm.2016.03.036. Epub 2016 Apr 4. Review.

PMID:
27055772
18.

Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.

Morissette M, Morin N, Grégoire L, Rajput A, Rajput AH, Di Paolo T.

Biochem Pharmacol. 2016 Jun 1;109:62-69. doi: 10.1016/j.bcp.2016.03.023. Epub 2016 Mar 30.

PMID:
27038656
19.

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.

Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569. Epub 2016 Mar 15.

PMID:
26990766
20.

Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice.

Miville-Godbout E, Bourque M, Morissette M, Al-Sweidi S, Smith T, Mochizuki A, Senanayake V, Jayasinghe D, Wang L, Goodenowe D, Di Paolo T.

PLoS One. 2016 Mar 9;11(3):e0151020. doi: 10.1371/journal.pone.0151020. eCollection 2016.

21.

Estrogen receptors modulate striatal metabotropic receptor type 5 in intact and MPTP male mice model of Parkinson's disease.

Al-Sweidi S, Morissette M, Di Paolo T.

J Steroid Biochem Mol Biol. 2016 Jul;161:84-91. doi: 10.1016/j.jsbmb.2016.02.004. Epub 2016 Feb 9.

PMID:
26873133
22.

Neuroactive gonadal drugs for neuroprotection in male and female models of Parkinson's disease.

Litim N, Morissette M, Di Paolo T.

Neurosci Biobehav Rev. 2016 Aug;67:79-88. doi: 10.1016/j.neubiorev.2015.09.024. Epub 2015 Dec 17. Review.

PMID:
26708712
23.

mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.

Morin N, Morissette M, Grégoire L, Di Paolo T.

Curr Neuropharmacol. 2016;14(5):481-93. Review.

24.

Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys.

Gagnon D, Gregoire L, Di Paolo T, Parent M.

Brain Struct Funct. 2016 Sep;221(7):3675-91. doi: 10.1007/s00429-015-1125-5. Epub 2015 Oct 13.

PMID:
26462663
25.

Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.

Morin N, Morissette M, Grégoire L, Rajput A, Rajput AH, Di Paolo T.

Neuropharmacology. 2015 Dec;99:356-68. doi: 10.1016/j.neuropharm.2015.08.002. Epub 2015 Aug 6.

PMID:
26254863
26.

Neuroprotective Effect of Progesterone in MPTP-Treated Male Mice.

Bourque M, Morissette M, Al Sweidi S, Caruso D, Melcangi RC, Di Paolo T.

Neuroendocrinology. 2016;103(3-4):300-14. doi: 10.1159/000438789. Epub 2015 Jul 24.

27.

GPER1-mediated immunomodulation and neuroprotection in the myenteric plexus of a mouse model of Parkinson's disease.

Côté M, Bourque M, Poirier AA, Aubé B, Morissette M, Di Paolo T, Soulet D.

Neurobiol Dis. 2015 Oct;82:99-113. doi: 10.1016/j.nbd.2015.05.017. Epub 2015 Jun 4.

PMID:
26051538
28.

The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.

Litim N, Bourque M, Al Sweidi S, Morissette M, Di Paolo T.

Neuropharmacology. 2015 Oct;97:86-94. doi: 10.1016/j.neuropharm.2015.05.015. Epub 2015 May 23.

PMID:
26006269
29.

Response.

Jourdain VA, Schechtmann G, Di Paolo T.

J Neurosurg. 2015 Apr;122(4):981-2. No abstract available.

PMID:
26000347
30.

Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.

Jourdain VA, Morin N, Grégoire L, Morissette M, Di Paolo T.

J Neurosurg. 2015 Dec;123(6):1383-93. doi: 10.3171/2014.10.JNS141570. Epub 2015 May 1.

PMID:
25932606
31.

Neuroprotection in Parkinsonian-treated mice via estrogen receptor α activation requires G protein-coupled estrogen receptor 1.

Bourque M, Morissette M, Di Paolo T.

Neuropharmacology. 2015 Aug;95:343-52. doi: 10.1016/j.neuropharm.2015.04.006. Epub 2015 Apr 17.

PMID:
25892506
32.

Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys.

Grégoire L, Smith T, Senanayake V, Mochizuki A, Miville-Godbout E, Goodenowe D, Di Paolo T.

Behav Brain Res. 2015 Jun 1;286:328-37. doi: 10.1016/j.bbr.2015.03.012. Epub 2015 Mar 11.

PMID:
25771209
33.

In memoriam: Paul J. Bedard, MD PhD (1942-2014).

Di Paolo T, Blanchet PJ.

Parkinsonism Relat Disord. 2015 May;21(5):429. doi: 10.1016/j.parkreldis.2015.01.014. Epub 2015 Jan 31. No abstract available.

PMID:
25737206
34.

Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.

Morin N, Di Paolo T.

Int Rev Neurobiol. 2014;119:151-67. doi: 10.1016/B978-0-12-801022-8.00007-6.

PMID:
25175965
35.

Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys.

Jourdain VA, Morin N, Morissette M, Grégoire L, Di Paolo T.

Exp Neurol. 2014 Nov;261:816-25. doi: 10.1016/j.expneurol.2014.08.018. Epub 2014 Aug 27.

PMID:
25172808
36.

AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.

Di Paolo T, Grégoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B.

Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23. doi: 10.1016/j.parkreldis.2014.05.007. Epub 2014 May 22.

PMID:
25172125
37.

Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates.

Morin N, Di Paolo T.

Front Neurol. 2014 Aug 5;5:144. doi: 10.3389/fneur.2014.00144. eCollection 2014. Review.

38.

Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.

Morin N, Morissette M, Grégoire L, Di Paolo T.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jan 2;56:27-38. doi: 10.1016/j.pnpbp.2014.07.006. Epub 2014 Jul 19.

PMID:
25046277
39.

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.

Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B.

Parkinsonism Relat Disord. 2014 Sep;20(9):947-56. doi: 10.1016/j.parkreldis.2014.05.003. Epub 2014 May 14. Review.

PMID:
24951359
40.

Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.

Bourque M, Morissette M, Di Paolo T.

Neurobiol Aging. 2014 Oct;35(10):2347-56. doi: 10.1016/j.neurobiolaging.2014.03.017. Epub 2014 Mar 20.

PMID:
24726471
41.

Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.

Morin N, Jourdain VA, Morissette M, Grégoire L, Di Paolo T.

Neuropharmacology. 2014 Apr;79:688-706. doi: 10.1016/j.neuropharm.2014.01.014. Epub 2014 Jan 20.

PMID:
24456747
42.

Subthalamotomy in the treatment of Parkinson's disease: clinical aspects and mechanisms of action.

Jourdain VA, Schechtmann G, Di Paolo T.

J Neurosurg. 2014 Jan;120(1):140-51. doi: 10.3171/2013.10.JNS13332. Epub 2013 Nov 8. Review.

PMID:
24205909
43.

Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.

Riahi G, Morissette M, Samadi P, Parent M, Di Paolo T.

Biochem Pharmacol. 2013 Oct 1;86(7):970-8. doi: 10.1016/j.bcp.2013.08.005. Epub 2013 Aug 14.

PMID:
23954709
44.

Metabotropic glutamate receptors for Parkinson's disease therapy.

Gasparini F, Di Paolo T, Gomez-Mancilla B.

Parkinsons Dis. 2013;2013:196028. doi: 10.1155/2013/196028. Epub 2013 Jun 19.

45.

Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.

Morin N, Morissette M, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.

Neuropharmacology. 2013 Oct;73:216-31. doi: 10.1016/j.neuropharm.2013.05.028. Epub 2013 Jun 10.

PMID:
23756168
46.

Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys.

Sánchez MG, Morissette M, Di Paolo T.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:170-7. doi: 10.1016/j.pnpbp.2013.05.008. Epub 2013 May 26.

PMID:
23719069
47.

Oestradiol modulation of serotonin reuptake transporter and serotonin metabolism in the brain of monkeys.

Sánchez MG, Morissette M, Di Paolo T.

J Neuroendocrinol. 2013 Jun;25(6):560-9. doi: 10.1111/jne.12034.

PMID:
23414342
48.

Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.

Grégoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T.

Parkinsonism Relat Disord. 2013 May;19(5):508-14. doi: 10.1016/j.parkreldis.2013.01.009. Epub 2013 Feb 9.

PMID:
23402994
49.

Modeling dyskinesia in animal models of Parkinson disease.

Morin N, Jourdain VA, Di Paolo T.

Exp Neurol. 2014 Jun;256:105-16. doi: 10.1016/j.expneurol.2013.01.024. Epub 2013 Jan 27. Review.

PMID:
23360802
50.

Estrogen receptors and lesion-induced response of striatal dopamine receptors.

Al Sweidi S, Morissette M, Rouillard C, Di Paolo T.

Neuroscience. 2013 Apr 16;236:99-109. doi: 10.1016/j.neuroscience.2012.12.058. Epub 2013 Jan 26.

PMID:
23357113

Supplemental Content

Loading ...
Support Center